Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies a...( ALICAFORSEN 127 APF 530 128 CRO...),Health

ALICAFORSEN 127

APF 530 128

CROFELEMER 128

HUMIRA 128

LINACLOTIDE 128

METHYLNALTREXONE (MNTX) (RELSTAR) 128

MLN 0002 (VEDOLIZUMAB) 129

ORBEC 129

PROCHYMAL 129

RENZAPRIDE 129

REMICADE 130

REZULAR 130

RIFAXIMAN (XIFAXAN) 130

SUTENT 130

ALICAFORSEN ENEMA 130

DEXTOFISOPAM 131

EKB-569 131

GTI-2040 131

PUMOSETRAG 131

RDP-58 132

SORAPRAZAN 132

TALNETANT 132

BL-1030 132

BL-1050 132

TABLE 52 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT 133

TABLE 52 (CONTINUED) 134

TABLE 52 (CONTINUED) 135

TABLE 52 (CONTINUED) 136

TABLE 52 (CONTINUED) 137

TABLE 52 (CONTINUED) 138

TABLE 52 (CONTINUED) 139

TOTAL MARKET ANALYSIS 139

TABLE 53 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER MARKET BY CATEGORY, THROUGH 2014 ($ MILLIONS) 139

FIGURE 32 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY CATEGORY, 2007-2014 ($ MILLIONS) 140

Chapter-6: INDUSTRY PARTICIPANTS BY PRODUCT TYPE

TABLE 54 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS' REVENUES AND MARKET SHARE BY TYPE, 2009 ($ MILLIONS/%) 141

FIGURE 33 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS' MARKET SHARE BY TYPE, 2009 (%) 142

COMPANY PROFILES 142

ASTRAZENECA 142

History 143

AXCAN PHARMA, INC. 143

History 144

CENTOCOR, INC. 145

History 146

EISAI, INC. 146

History 147

GENENTECH, INC. 147

History 148

GLAXOSMITHKLINE 148

Glaxosmithkline (Continued) 149

Glaxosmithkline (Continued) 150

History 151

JOHNSON & JOHNSON 151'/>"/>